Silvia Jiménez Cabrera

Silvia Jiménez Cabrera

Auto-generated profile, based on publicly available information

Silvia Jiménez Cabrera

Pharmacy Service University Hospital of Salamanca Salamanca Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Annals of Oncology
Verified
Journal Article
Closed access
Ramon Garcia-SanzRamon Garcia-Sanz
Ramon Garcia-Sanz
ASA. Sureda
A. Sureda
FCF. de la Cruz
F. de la Cruz
MCM. Canales
M. Canales
AGA.P. Gonzalez
A.P. Gonzalez
CMC. Martinez
C. Martinez
In this work, we assessed the efficacy and safety of brentuximab vedotin (BV) plus ESHAP (BRESHAP) as second-line therapy for Relapsed/Refractory Hodgkin lymphoma (RRHL) to improve the results before autologous stem-cell transplantation (ASCT). This was a multicenter, open-label, phase I-II trial of patients with RRHL after first-line chemotherapy. Treatment had three 21-day cycles of etoposide, solumedrol, high-dose AraC, and cisplatin. BV was administered at three dose levels (0.9, 1.2, and 1.8 mg/kg) intravenous on day ‒1 to 3 + 3 cohorts of patients. Final BV dose was 1.8 mg/kg. Responding patients proceeded to ASCT, followed by three BV courses (1.8 mg/kg, every 21 days). Main end points for evaluation were maximum tolerable dose and overall and complete response (CR) before ASCT. A total of 66 patients were recruited (median age 36 years; range 18-66): 40 were primary refractory, 16 early relapse and 10 late relapse. There were 39 severe adverse events were reported in 22 patients, most frequently fever (n = 25, 35% neutropenic), including 3 deaths. Grade 3-4 hematological toxicity presented in 28 cases: neutropenia (n = 21), thrombocytopenia (n = 14), and anemia (n = 7). Grade ≥3-4 extrahematological adverse events (≥5%) were non-neutropenic fever (n = 13) and hypomagnesaemia (n = 3). Sixty-four patients underwent stem-cell mobilization; all collected >2×10e6/kg CD34+ cells (median 5.75; range 2.12-33.4). Overall response before transplant was 91% (CI 84% to 98%), including 70% (CRs 95% CI 59% to 81%). 60 patients were transplanted with no failure engraftments. Post-transplant response was CR in 49 patients (82% CI 73% to 91%) and partial responses in six (10% CI 5% to 15%). After a mean follow-up of 27 months, the 30-month time to treatment to failure was 74% (95% CI 68% to 80%), progression-free survival 71% (95% CI 65% to 77%), and overall survival 91% (CI 84% to 98%). BRESHAP looks a safe and effective pre-transplant induction regimen, does not jeopardize transplant and allows long-term remissions and survival.

27 October 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
AAAlvaro Corral Alaejos
Alvaro Corral Alaejos
ACAránzazu Zarzuelo Castañeda
Aránzazu Zarzuelo Castañeda
SCSilvia Jiménez Cabrera
Silvia Jiménez Cabrera
FSFermin Sanchez-Guijo
Fermin Sanchez-Guijo
MOMaría José Otero
María José Otero
Jonás Pérez-BlancoJonás Pérez-Blanco
Jonás Pérez-Blanco
Aims: Imatinib is considered the standard first‐line treatment in newly diagnosed patients with chronic‐phase myeloid leukaemia (CML). Several imatinib population pharmacokinetic (popPK) models have been developed. However, their predictive performance has not been well established when extrapolated to different populations. Therefore, this study aimed to perform an external evaluation of available imatinib popPK models developed mainly in adult patients, and to evaluate the improvement in individual model‐based predictions through Bayesian forecasting computed by each model at different treatment occasions.Methods: A literature review was conducted through PubMed and Scopus to identify popPK models. Therapeutic drug monitoring data collected in adult CML patients treated with imatinib was used for external evaluation, including prediction‐ and simulated‐based diagnostics together with Bayesian forecasting analysis.Results: Fourteen imatinib popPK studies were included for model‐performance evaluation. A total of 99 imatinib samples were collected from 48 adult CML patients undergoing imatinib treatment with a minimum of one plasma concentration measured at steady‐state between January 2016 and December 2020. The model proposed by Petain et al showed the best performance concerning prediction‐based diagnostics in the studied population. Bayesian forecasting demonstrated a significant improvement in predictive performance at the second visit. Inter‐occasion variability contributed to reducing bias and improving individual model‐based predictions.Conclusions: Imatinib popPK studies developed in Caucasian subjects including α1‐acid glycoprotein showed the best model performance in terms of overall bias and precision. Moreover, two imatinib samples from different visits appear sufficient to reach an adequate model‐based individual prediction performance trough Bayesian forecasting.

1 October 2008 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
MPMaria J. Perez
Maria J. Perez
BCBeatriz Castaño
Beatriz Castaño
SJSilvia Jimenez
Silvia Jimenez
MSMaria A Serrano
Maria A Serrano
JGJose M. Gonzalez-Buitrago
Jose M. Gonzalez-Buitrago
Jose MarinJose Marin
Jose Marin

1 February 2005 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
Rocio MaciasRocio Macias
Rocio Macias
MSMaria A Serrano
Maria A Serrano
MMMaria J. Monte
Maria J. Monte
SJSilvia Jimenez
Silvia Jimenez
BHBelen Hernandez
Belen Hernandez
Jose MarinJose Marin
Jose Marin
Transient latent cholestasis in young rats born from mothers with obstructive cholestasis during pregnancy (OCP) has been reported. The cause of this congenital impairment and the long-term effect on the pups of treating their mothers with ursodeoxycholic acid (UDCA) during pregnancy were investigated. Complete biliary obstruction was imposed on day 14 of pregnancy and UDCA treatment was begun on day 15. Serum bile acids (BAs) concentrations were elevated in 4-week-old pups born from OCP, but not OCP + UDCA, mothers. However, gas chromatographic/mass spectrometric analysis of BA species in basal bile indicated the presence of significant differences among all experimental groups (control, OCP, and OCP + UDCA). Canalicular plasma membrane fluidity was reduced in OCP, but not in OCP + UDCA, pups. Screening by reverse transcription followed by real-time quantitative polymerase chain reaction of the steady-state levels of mRNA of genes related to hepatobiliary function revealed changes (upregulation of Cyp7a1 and Mrp1 and down-regulation of Abcg5 and Abcg8) in OCP group, which were prevented by UDCA treatment. Electron microscopy examination showed multilamellar bodies occupying part of the canalicular lumen in OCP pups. Their number and size were reduced in animals born from OCP + UDCA mothers. In OCP, but not OCP + UDCA, the stimulation of bile flow and BA output induced by taurocholate administration were reduced and cholesterol/BA output ratio was increased, whereas phospholipid/BA output ratio was enhanced in both groups (OCP > OCP + UDCA). In conclusion, UDCA treatment of rats with cholestasis during pregnancy has long-term beneficial effects on their offspring by preventing in part the congenital impairment in hepatobiliary function of the pups that affects their biliary lipid secretion.

5 April 2021 in Chromatographia
Verified
Journal Article
Closed access
PDF file
AAAlvaro Corral Alaejos
Alvaro Corral Alaejos
SCSilvia Jiménez Cabrera
Silvia Jiménez Cabrera
BRBeatriz Castaño Rodríguez
Beatriz Castaño Rodríguez
ACAránzazu Zarzuelo Castañeda
Aránzazu Zarzuelo Castañeda